8-Quinoline carbanilates for the inhibition of lipolysis
申请人:USV Pharmaceutical Corp.
公开号:US04530931A1
公开(公告)日:1985-07-23
##STR1## and pharmaceutically acceptable salts thereof wherein: R.sub.1 is H, alkyl, alkoxy, trihalomethyl, and chlorine; X is in the 8 position and is O(CH.sub.2).sub.n, N(CH.sub.2).sub.n ; Y is O(CH.sub.2).sub.n, N(CH.sub.2).sub.n ; R.sub.2 is monosubstituted or independently disubstituted H, carboxyl, or alkylcarboxy; Z is 0; and n is 0 to 10 inclusive, useful in the treatment of ischemic heart disease and hypertriglyceridemia.
Synthesis and antilipolytic activities of quinolyl carbanilates and related analogs
作者:John H. Musser、Utpal Chakraborty、Kevin Bailey、Stan Sciortino、Carol Whyzmuzis、Dilip Amin、Charles A. Sutherland
DOI:10.1021/jm00384a011
日期:1987.1
A series of quinolyl carbanilates was prepared and tested as antilipolytic agents. These compounds inhibited production of glycerol from rat adipocytes and inhibited liberation of free fatty acids from triolein by canine cardiac triglyceride lipases. An extensive structure-activity relationship study indicated that 8-quinolyl 4-methoxycarbanilate (1) contained features necessary for maximum potency